Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”

ABSTRACT

In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico. This comment addresses Gomez et. al.’s comments with additional information and clarifies potential misinterpretations.

KEYWORDS:

• Economic Evaluation
• Pneumococcal Conjugate Vaccine
• Cost-effectiveness

Disclosure of potential conflicts of interest

M Wasserman, MG Palacios, AG Grajales and R Farkouh, are employees of Pfizer Inc. M Wilson and C McDade are employees of RTI Health Solutions are were paid as consultants as part of this study.